A best evidence topic was written according to a structured protocol. The question addressed was whether embolization is superior to surveillance for a type II endoleak associated with a static sac size post-endovascular abdominal aortic aneurysm repair (EVAR). Four hundred and sixty-one papers were identified, of which 10 papers presented the best evidence to answer the clinical question. The author, journal, date and country of publication, patient group studied, study type, and relevant outcomes and results are tabulated. A review of the available literature suggests that most type II endoleaks are innocuous and will seal spontaneously during the long-term follow-up, even when they persist for more than 6 months. An analysis of the large European Collaborators on Stent-Graft Techniques for Aortic Aneurysm Repair (EUROSTAR) registry that includes prospective data on 2463 patients from 87 European hospitals showed that type II endoleaks were not associated with an increased risk of rupture; this correlates well with the large single-centre studies included in this review. Based on the available evidence, we conclude that the management of most isolated type II endoleaks should be conservative-with close radiological follow-up-even when persistent, with intervention restricted to theoese associated with sac enlargement >5 mm over a 6-month period or >10 mm when compared with pre-EVAR diameter.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol as previously described [1] .
CLINICAL SCENARIO
A 75-year-old male patient has an elective endovascular repair (EVAR) for a 7.2-cm abdominal aortic aneurysm. A small type II endoleak identified at the end of the procedure was not treated. On the post-procedural and 6-month follow-up CT angiography, there is still evidence of the type II endoleak, but the aneurysm sac size is unchanged. The case is discussed at the vascular multi-disciplinary meeting and you are asked whether percutaneous embolization should be attempted. You are unsure whether there is any evidence to suggest that embolization is superior to conservative management for such a case. You decide to carry out a literature search to find the best available clinical evidence to manage the patient. 
THREE-PART QUESTION

SEARCH OUTCOME
Four hundred and sixty-one papers were found using the reported search. From these, 10 papers were identified that provided the best evidence to answer the question. These are presented in Table 1 . The relevant papers included one meta-analysis, one multicentre study and eight retrospective single-centre studies.
RESULTS
The boundaries of the anatomical and clinical suitability for EVAR are being pushed and as a result, patients with increasingly tortuous vascular anatomy and younger patients with less surgical co-morbidity are being offered EVAR. The recent publication of the long-term outcomes of the EVAR trials has shown a Gelfand et al. [5] performed a meta-analysis of 10 EVAR trials in 2006, involving a total of 2617 cases. The incidence of type II endoleak at 30 days was 6-17%, which steadily decreased to 1.5% at 1 year. They found no association between ruptures and type II endoleak. They recommend that type II endoleaks be followed for up to 12 months, expecting that most will disappear spontaneously. If sac enlargement occurs after 6 months, percutaneous intervention should be considered. Persistent type II endoleaks without sac enlargement may be followed closely with CT or ultrasound surveillance. Definitive elective treatment is indicated if the endoleak persists for >12 months. Indications for early intervention include a symptomatic or pulsatile sac or sac enlargement of >5 mm over a 6-month period.
Van Marrewijk et al. [6] analysed the data of 2463 patients from 87 European institutions that collaborated in the EUROSTAR registry. At 3-year post-EVAR, they showed that a type II endoleak was not associated with conversion to open repair or sac rupture. The authors conclude that secondary intervention is not indicated for type II endoleak unless the aneurysm clearly shows expansion. However, they define significant sac expansion as ≥8 mm maximum transverse diameter increase over pre-procedure measurements compared with the majority of other studies which used ≥5 mm [5, [7] [8] [9] . Similarly, Steinmetz et al. [10] also showed that the conservative approach of embolizing a type II endoleak only when persistent (i.e. more than 6 months) and associated with an aneurysm sac growth of ≥5 mm was safe. However, their median follow-up was only 22 months and there is increasing evidence to show that late complications and rupture can occur up to 8 years after EVAR [3] . Silverberg et al. [7] , Rayt et al. [8] and Tolia et al. [11] also showed that type II endoleaks have a relatively benign course if the sac size remains static and that the rate of spontaneous seal continues to increase with time and the close follow-up of patients. Jones et al. [12] found a clear distinction between persistent type II endoleak (>6 months) and those that sealed spontaneously within 6 months with no evidence of sac expansion. The latter were found to be innocuous and not associated with any increased was associated with an increased morbidity or mortality, while the former was associated with an increased incidence of aneurysm sac growth and re-intervention rate.
Sarac et al. [13] analysed the outcome and long-term success of treating type II endoleaks. They advocate early treatment for type II endoleaks that are associated with an increase in sac size. However, even in this sub-group of patients who have their initial type II endoleak successfully treated, continued surveillance is important as up to 20% had recurrence that required further treatment at 5-year post-EVAR.
CLINICAL BOTTOM LINE
The available evidence suggests that the majority of isolated type II endoleaks are innocuous and will seal spontaneously during the long-term follow-up, even when they persist for more than 6 months, and the vast majority of studies have not demonstrated an association with the increased risk of rupture or aneurysm-related mortality. However, if a type II endoleak is associated with a significant sac enlargement (i.e. >5 mm over a 6-month period), intervention is indicated, usually in the form of a percutaneous embolization of the feeding vessels. The caveat is that there is no randomized data and that most studies had a 
